Never miss out on the latest news!
Sign up to the Thrombosis Adviser newsletter.
Vascular disease and its many manifestations, including coronary artery disease (CAD) and peripheral artery disease (PAD), have a major impact on the lives of millions of patients and those around them. Major advances in surgical and medical management strategies have helped healthcare professionals reduce its impact. However, despite these advances, the residual risk of major adverse cardiac events remains high. Research into innovative strategies to address this residual risk is ongoing. Whether it is through the use of different combinations of antithrombotic drugs, reducing lipid levels or other disease mediators, the area of Vascular Protection is exciting and continues to evolve.
Find out how the combined risk of lower limb ischaemia and major cardiovascular events following peripheral revascularization was reduced in patients with symptomatic PAD in the VOYAGER PAD trial
Find out how the risk of cardiovascular events was reduced in patients with CAD and PAD in the COMPASS trial